Sign In
Buy ACON
$3.49
-0.0100 (-0.286%)
At Close: Jun 03, 2026
Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
07:00am, Tuesday, 24'th Jun 2025
BROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and prop
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
06:00am, Tuesday, 20'th May 2025
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrat
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
07:34am, Monday, 12'th May 2025
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability
Aclarion Welcomes Advocate Health as CLARITY Trial Site
06:00am, Monday, 05'th May 2025
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcome
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
06:00am, Tuesday, 29'th Apr 2025
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025
06:00am, Wednesday, 23'rd Apr 2025
BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and pr
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
06:00am, Monday, 21'st Apr 2025
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgic
